Multiple myeloma (MM) is the biggest normal cancer influencing the bone marrow and remains fatal for maximum patients, hence innovative therapies are taken. Bortezomib is an FDA-permitted drug for the therapy of patients with MM. We emphasized an alternative convergent method is developed for the synthesis of bortezomib molecule. The targeted compound was achieved with excellent yields, improved reaction conditions and mild reagents.